ClinicalTrials.gg
CompletedNCT01723904Updated Jun 3, 2014Results posted

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Advanced Parkinson's Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 22 sites in 5 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-03.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
23rd of 42
90 · median 123
Started
2012
with 7 others
Phase 3
20 of 44
none open now
Registered
32nd of 44
by date
Lead sponsor
5 of 44
UCB BIOSCIENCES GmbH

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 23rd largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 20 in phase 3, and was the 32nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.

03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, aged ≥ 30 and \< 80 years at
  • Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of Parkinsonism
  • Subject has motor fluctuations such as wearing, dyskinesia
  • Subject has experienced nocturias for at least 3 nights within 7 days prior to Baseline
  • Subject is taking levodopa (L-DOPA, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of L-DOPA for at least 28 days prior to Baseline (Visit 2)
  • Subject is taking a non-ergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole ≤ 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least 28 days prior to Baseline (Visit 2)

Exclusion criteria

Exclusion Criteria:

  • Subject is receiving therapy with tolcapone or budipine
  • Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine
  • Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to Baseline (Visit 2)
  • Subject has a known to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis
  • Subject is pregnant or nursing, or is of (ie, is (i) not surgically sterile, or, (ii) not using adequate methods [including at least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal)
  • Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Rotigotine

    - Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period. Duration of the Titration Period: Between 1 week and 5 weeks. - Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period. Duration of the Maintenance Period: Between 3 weeks and 7 weeks.

    Drug: Rotigotine

Interventions

  • Application of Rotigotine up to 8 mg/24 h patches for 24 hours.

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period

    The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable 1. = No side effects 2. = Side effects do not significantly interfere with subject's functioning 3. = Side effects significantly interfere with the subject's functioning 4. = Side effects outweigh therapeutic efficacy.

    Time frame: Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

  2. Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score

    The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108. A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

  3. Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score

    UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible). UPDRS Part II total score (average of "on" and "off" state) is the average of UPDRS Part II total score ("on" state) and Part II total score ("off" state). A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

  4. Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"

    Absolute time spent "off" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent "off" decreased from Baseline and therefore indicates an improvement from Baseline. Only subjects with time spent "off" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

Secondary outcomes

  1. Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia

    Absolute time spent "on" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent "on" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

  2. Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score

    The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions. A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

  3. Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score

    The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.

    Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)

07

Results

Posted Jun 3, 2014

Participant flow

This multicenter study started to enroll subjects in 5 countries in October 2012.

Participant flow — Overall Study
MilestoneRotigotine
Started90
Completed79
Not completed11
Withdrew: Noncompliant3
Withdrew: Adverse event5
Withdrew: Unable to follow protocol/ judged by inv3

Outcome measures

PrimaryClinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period

The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable 1. = No side effects 2. = Side effects do not significantly interfere with subject's functioning 3. = Side effects significantly interfere with the subject's functioning 4. = Side effects outweigh therapeutic efficacy.

Time frame:
Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Number · participants
Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period
participantsRotigotine
CGI Item 4 score of 161
CGI Item 4 score of 222
CGI Item 4 score of 33
CGI Item 4 score of 43
CGI Item 4 score of 3 or 46
PrimaryChange From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score

The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108. A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · units on a scale
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score
units on a scaleRotigotine
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score-5.3 ± 8.3
PrimaryChange From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score

UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible). UPDRS Part II total score (average of "on" and "off" state) is the average of UPDRS Part II total score ("on" state) and Part II total score ("off" state). A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · units on a scale
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score
units on a scaleRotigotine
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score-1.5 ± 3.8
PrimaryChange From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"

Absolute time spent "off" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent "off" decreased from Baseline and therefore indicates an improvement from Baseline. Only subjects with time spent "off" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · hours/day
Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"
hours/dayRotigotine
Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"-2.1 ± 2.9
SecondaryChange From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia

Absolute time spent "on" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent "on" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · hours/day
Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia
hours/dayRotigotine
Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia1.9 ± 3.1
SecondaryChange From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score

The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions. A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · units on a scale
Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score
units on a scaleRotigotine
Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score-3.2 ± 7.5
SecondaryChange From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score

The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.

Time frame:
From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Reported as:
Mean · units on a scale
Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score
units on a scaleRotigotine
Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score-0.7 ± 3.0

Adverse events

Collected over Adverse Events (AEs) were collected over the whole study duration from the Screening Period (Day -28 to Day -7) to the Safety Follow-up Visit (up to Day 78).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—5/90 (5.6%)35/90 (38.9%)
Most frequent serious events
Most frequent serious events
EventRotigotine
Subdural haemorrhageInjury, poisoning and procedural complications1/90
Nasopharyngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90
Confusional statePsychiatric disorders1/90
DeliriumPsychiatric disorders1/90
HallucinationPsychiatric disorders1/90
Urinary retentionRenal and urinary disorders1/90
Most frequent other events
Most frequent other events
EventRotigotine
Application site pruritusGeneral disorders12/90
DizzinessNervous system disorders9/90
Orthostatic hypotensionVascular disorders9/90
NauseaGastrointestinal disorders7/90
DyskinesiaNervous system disorders7/90
NasopharyngitisInfections and infestations5/90

Baseline characteristics

Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application.

Age, Continuous
Age, Continuous(years)Rotigotine
Mean61.3 ± 9.3
Age, Customized
Age, Customized(participants)Rotigotine
< 65 years57
>= 65 years33
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female43
Male47
Region of Enrollment
Region of Enrollment(participants)Rotigotine
Taiwan8
Malaysia6
Singapore4
Australia6
Korea, Republic of66
08

Study locations

22 sites
  • 402
    Chatswood, New South Wales, Australia
  • 401
    Sydney, New South Wales, Australia
  • 403
    Melbourne, Victoria, Australia
  • 104
    Busan, Korea, Republic of
  • 112
    Busan, Korea, Republic of
  • 109
    Daegu, Korea, Republic of
  • 111
    Gyeonggi-Do, Korea, Republic of
  • 101
    Seoul, Korea, Republic of
  • 102
    Seoul, Korea, Republic of
  • 103
    Seoul, Korea, Republic of
  • 105
    Seoul, Korea, Republic of
  • 107
    Seoul, Korea, Republic of
  • 108
    Seoul, Korea, Republic of
  • 110
    Seoul, Korea, Republic of
  • 202
    Kuala Terengganu, Malaysia
  • 204
    Kuching Sarawak, Malaysia
  • 201
    Pulau Pinang, Malaysia
  • 501
    Singapore, Singapore
  • 502
    Singapore, Singapore
  • 302
    Taichung, Taiwan
  • 303
    Tainan, Taiwan
  • 306
    Taipei, Taiwan
09

References and documents

Publications

  • Kim JM, Chung SJ, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L; Asia Pacific Rotigotine Add-on Study Group. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study. BMC Neurol. 2015 Feb 28;15:17. doi: 10.1186/s12883-015-0267-7. PubMed 25879416 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Mar 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2012
First posted
Nov 8, 2012
Start
Oct 2012
Primary completionActual
Mar 2013
CompletionActual
Apr 2013
Results first posted
Jun 3, 2014
Last update
Jun 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01723904
Responsible party
Sponsor
First posted
Nov 8, 2012
Start date
Oct 2012
Primary completion
Mar 2013
Completion
Apr 2013
Results posted
Jun 3, 2014
Last update
Jun 3, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion